Overview
flowchart TD
PSP["PSP"] -->|"associated with"| Alzheimer["Alzheimer"]
PSP["PSP"] -->|"associated with"| Als["Als"]
PSP["PSP"] -->|"associated with"| Alzheimer_s_disease["Alzheimer's disease"]
PSP["PSP"] -->|"expressed in"| neurons["neurons"]
PSP["PSP"] -->|"downregulates"| SV2A["SV2A"]
PSP["PSP"] -->|"targets"| tauopathy["tauopathy"]
PSP["PSP"] -->|"participates in"| unfolded_protein_response["unfolded protein response"]
PSP["PSP"] -->|"regulates"| STX6["STX6"]
PSP["PSP"] -->|"associated with"| frontotemporal_dementia["frontotemporal dementia"]
PSP["PSP"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
PSP["PSP"] -->|"associated with"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"regulates"| Parkinson_s_disease["Parkinson's disease"]
PSP["PSP"] -->|"associated with"| tauopathy["tauopathy"]
PSP["PSP"] -->|"biomarker for"| Ms["Ms"]
style PSP fill:#4fc3f7,stroke:#333,color:#000| Globus Pallidus Neurons in Progressive Supranuclear Palsy | |
|---|---|
| Taxonomy | ID |
| Cell Ontology (CL) | [CL:4042028](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4042028) |
| PSP Subtype | GPi Tau Burden |
| Richardson syndrome (PSP-RS) | +++ (severe) |
| PSP-Parkinsonism (PSP-P) | ++ (moderate) |
| PSP-PAGF | ++ (moderate) |
| PSP-frontal (PSP-F) | + (mild) |
The globus pallidus (GP) is a principal output nucleus of the basal ganglia that undergoes severe degeneration in Progressive Supranuclear Palsy (PSP). Both segments — the external (GPe) and internal (GPi) — accumulate dense 4-repeat (4R) tau pathology including globose neurofibrillary tangles, tufted astrocytes, and coiled bodies
Multi-Taxonomy Classification
Taxonomy Database Cross-References
Morphology & Electrophysiology
-
Morphology: immature neuron (source: Cell Ontology)
-
Morphology can be inferred from Cell Ontology classification
-
External Database Links
Neuroanatomy and Normal Function
External Segment (GPe)
The GPe occupies the lateral portion of the globus pallidus and receives the bulk of striatal indirect-pathway input. Its neurons are tonically active GABAergic projection cells firing at 50-70 Hz1Primate models of movement disorders of basal ganglia originOpen reference. Key connections include:
-
Input: GABAergic projections from striatal D2-expressing medium spiny neurons (indirect pathway)
-
Output: Inhibitory projections to the STN, GPi, and striatum
-
Two subtypes: Prototypic neurons (project to STN) and arkypallidal neurons (project back to striatum), forming a dual feedback architecture2Dichotomous organization of the external globus pallidusOpen reference
-
Function: GPe acts as a central pacemaker of basal ganglia oscillatory activity; GPe-STN reciprocal connections generate beta-band (15-30 Hz) oscillations critical for movement gating
Internal Segment (GPi)
The GPi is one of two major output nuclei of the basal ganglia (alongside the substantia nigra pars reticulata). GPi neurons are tonically active at 60-80 Hz and provide sustained GABAergic inhibition to downstream targets3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference:
-
Input: Inhibitory from striatal D1-expressing MSNs (direct pathway); excitatory from STN (indirect and hyperdirect pathways)
-
Output: Thalamocortical pathway (ventrolateral and ventroanterior thalamic nuclei → motor and premotor cortex), pedunculopontine nucleus (PPN), and lateral habenula
-
Function: GPi is the final common path for basal ganglia motor output; its tonic inhibition is released (disinhibited) by striatal direct-pathway activation, permitting movement
Movement Control Mechanism
Voluntary movement requires coordinated GPi disinhibition:
-
Cortex activates striatal direct-pathway MSNs → inhibit GPi
-
GPi tonic firing decreases → thalamus released from inhibition
-
Thalamocortical neurons activate motor cortex → movement initiated
-
Simultaneously, the hyperdirect pathway (cortex → STN → GPi) provides a broad “surround inhibition” to suppress competing motor programs4Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathwayOpen reference
Pathological Changes in PSP
Tau Pathology
PSP produces dense 4R tau pathology throughout both GP segments5Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)Open reference6Neuropathology of variants of progressive supranuclear palsyOpen reference:
-
Globose neurofibrillary tangles: The hallmark PSP inclusion, with round or globular morphology. NFT density in the GP is among the highest of any brain region in PSP, rivalling the STN and pontine nuclei
-
Tufted astrocytes: PSP-specific astrocytic tau inclusions with radiating tau-positive processes, concentrated in the GP neuropil7Distribution patterns of tau pathology in progressive supranuclear palsyOpen reference
-
Coiled bodies: Oligodendroglial tau inclusions in pallidal white matter tracts (ansa lenticularis, lenticular fasciculus), representing tau propagation along myelinated axons
-
Neuropil threads: Dense tau-positive neurites reflecting degenerating pallidal dendrites and axon terminals
-
Ghost tangles: Extracellular NFT remnants of dead neurons, indicating advanced neurodegeneration
Neuronal Loss and Gliosis
Quantitative neuropathological studies demonstrate8Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonismOpen reference9Neuropathology of progressive supranuclear palsyOpen reference:
-
GPi: 30-50% neuronal loss, with remaining neurons showing shrunken cell bodies, dendritic retraction, and reduced firing rate
-
GPe: 20-40% neuronal loss, with more variable severity across PSP subtypes
-
Reactive astrogliosis: Dense GFAP-positive astrocytic proliferation, with tufted astrocytes interspersed among reactive astrocytes
-
Microglial activation: HLA-DR-positive microglia clustering around degenerating neurons and NFTs10Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degenerationOpen reference
-
Iron deposition: Increased pallidal iron detectable on susceptibility-weighted MRI, potentially catalysing oxidative damage and tau aggregation
Functional Consequences
GPi degeneration produces a complex motor phenotype2Dichotomous organization of the external globus pallidusOpen reference0:
-
Loss of tonic inhibition: Reduced GPi firing releases thalamic neurons from inhibition, but paradoxically produces akinesia because the loss of phasic GPi modulation (which normally selects specific movements by differential inhibition) impairs motor program selection
-
Beta oscillation pathology: Disrupted GPe-STN oscillatory coupling leads to abnormally increased beta-band synchrony, associated with akinesia and rigidity2Dichotomous organization of the external globus pallidusOpen reference1
-
PPN disinhibition: Loss of GPi inhibition of the PPN contributes to gait dysfunction, though PPN degeneration itself compounds this effect
-
Oculomotor disruption: GPi/SNr projections to the superior colliculus control saccade initiation; their loss contributes to vertical supranuclear gaze palsy
Clinical Manifestations
Motor Symptoms
Pallidal degeneration contributes to the core motor features of PSP2Dichotomous organization of the external globus pallidusOpen reference2:
-
Akinesia/bradykinesia: Slowness and poverty of movement, particularly for axial movements (turning, rising from a chair)
-
Axial rigidity: Marked neck and trunk rigidity, often with retrocollis (backward head extension) — a distinguishing feature from PD
-
Postural instability: Early backward falls, reflecting combined pallidal, STN, and PPN dysfunction; falls typically occur within the first year
-
Gait freezing: Sudden inability to initiate or continue walking, especially when turning or approaching narrow spaces
Relationship to PSP Subtypes
Pallidal pathology severity varies across clinical phenotypes2Dichotomous organization of the external globus pallidusOpen reference3:
Molecular Mechanisms of Vulnerability
Selective Vulnerability Factors
Several features of GP neurons confer vulnerability to tauopathy2Dichotomous organization of the external globus pallidusOpen reference4:
-
High tonic firing rate: 60-80 Hz sustained discharge creates extreme metabolic demand and mitochondrial oxidative stress
-
Dense glutamatergic input from STN: Excitotoxic vulnerability from sustained excitatory bombardment; as STN degenerates, aberrant firing patterns may exacerbate damage
-
MAPT H1 haplotype: The H1 haplotype increases 4R tau expression, and GP neurons express high baseline levels of tau protein2Dichotomous organization of the external globus pallidusOpen reference5
-
Iron content: The GP has the highest iron concentration of any brain structure, creating a pro-oxidative environment that promotes tau aggregation via Fenton chemistry2Dichotomous organization of the external globus pallidusOpen reference6
-
Network centrality: As a convergence point for direct, indirect, and hyperdirect pathways, the GP is exposed to tau propagation from multiple sources simultaneously
Tau Propagation Pathways
The GP’s extensive connectivity facilitates prion-like tau spread:
-
Striatum → GPe/GPi: Striatopallidal GABAergic projections deliver tau from the striatum
-
STN → GPi: Dense glutamatergic STN-GPi projections provide bidirectional tau propagation
-
GPe ↔ STN: The pallidosubthalamic loop enables reciprocal tau seeding between these two severely affected nuclei
-
GPi → thalamus: Pallidothalamic fibres (ansa lenticularis, lenticular fasciculus) transport tau to thalamic nuclei
-
GPi → PPN: Pallidopontine projections seed the brainstem locomotor centre
Biomarkers and Neuroimaging
Structural MRI
-
Pallidal atrophy: Detectable on volumetric MRI, correlating with disease severity2Dichotomous organization of the external globus pallidusOpen reference7
-
Susceptibility-weighted imaging (SWI): Increased pallidal iron deposition visible as hypointensity
-
Midbrain-pons ratio: Global basal ganglia atrophy pattern supports PSP diagnosis
Molecular Imaging
-
FDG-PET: Pallidal and frontal hypometabolism distinguishes PSP from PD2Dichotomous organization of the external globus pallidusOpen reference8
-
Tau PET: ¹⁸F-flortaucipir shows elevated binding in the pallidum, though off-target neuromelanin and MAO-B binding complicate interpretation
-
DAT-SPECT: Reduced striatal dopamine transporter binding reflecting nigrostriatal degeneration, with more symmetric pattern than PD
Therapeutic Implications
Symptomatic Management
-
Levodopa: Limited benefit due to post-synaptic degeneration of pallidal output circuits; trial of up to 1000 mg/day warranted2Dichotomous organization of the external globus pallidusOpen reference9
-
Amantadine: NMDA antagonist providing modest improvement in akinesia (100-300 mg/day)
-
Physical therapy: Most effective intervention — gait training, balance exercises, and weighted walkers reduce fall risk
-
Deep brain stimulation: GPi-DBS has been attempted in select PSP patients but shows limited and variable benefit because the target neurons are themselves degenerating3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference0
Disease-Modifying Approaches
-
Anti-tau immunotherapy: Tilavonemab, semorinemab — targeting extracellular tau to block prion-like spread through pallidal circuits3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference1
-
Tau ASOs: BIIB080 targeting MAPT mRNA to reduce tau production in vulnerable GP neurons
-
Autophagy enhancers: Rapamycin and lithium to promote clearance of intracellular tau aggregates
-
Neuroprotective agents: Iron chelators (deferiprone) to address the GP’s uniquely high iron burden
CBS/PSP Overlap
In corticobasal syndrome (CBS), GP degeneration may be asymmetric, contributing to the unilateral motor presentation. CBD pathology shows more cortical astrocytic plaques and less subcortical tau than PSP, but GP involvement is substantial in both disorders3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference2.
Cross-References
-
Progressive Supranuclear Palsy — Disease overview
-
Corticobasal Degeneration — Related 4R tauopathy
-
Globus Pallidus in CBD — CBD-specific pallidal pathology
-
Subthalamic Nucleus in PSP — Connected nucleus
-
Substantia Nigra in PSP
-
PPN Cholinergic Neurons in PSP
-
4R Tauopathy Mechanisms
Diseases
-
Progressive Supranuclear Palsy (PSP)
-
Corticobasal Syndrome (CBS
-
Corticobasal Degeneration (CBD
Mechanisms
-
Tauopathy
-
4R Tauopathy Molecular Mechanisms
Treatments
-
CBS/PSP Treatment Rankings
Cell Types
-
Progressive Supranuclear Palsy Neurons
-
Corticobasal Syndrome Neurons
-
Core disease pages: Corticobasal Syndrome, Corticobasal Degeneration, Progressive Supranuclear Palsy, Frontotemporal Dementia, Primary Age-Related Tauopathy
-
Mechanistic hubs: Tauopathy, 4R Tauopathy Molecular Mechanisms, Corticobasal Degeneration Pathway, Progressive Supranuclear Palsy Pathway, Cortisol-Tau Pathway, Gut-Brain Axis in Tauopathy, Selective Neuronal Vulnerability
-
Brain-region context: Cerebral Cortex, Basal Ganglia, Globus Pallidus, Substantia Nigra, Striatum, Subthalamic Nucleus, Pedunculopontine Nucleus
-
Biomarker hubs: Imaging Biomarkers for CBS/PSP, MRI Atrophy Patterns in CBS/PSP, Tau PET in CBS/PSP, DTI White Matter Changes in CBS/PSP, Biomarkers for Progressive Supranuclear Palsy, Biomarkers for Corticobasal Degeneration
-
Related cell-type pages: Striatal Interneurons in Corticobasal Degeneration, Globus Pallidus Neurons in Corticobasal Degeneration, Cortical Pyramidal Neurons in Corticobasal Degeneration, Substantia Nigra Neurons in Corticobasal Degeneration, Substantia Nigra Neurons in Progressive Supranuclear Palsy, Globus Pallidus Neurons in Progressive Supranuclear Palsy, Pedunculopontine Nucleus Cholinergic in PSP, Locus Coeruleus Noradrenergic in PSP, Nigral Microglia in PSP, Tauopathy-Associated Neurons
-
Treatment hubs: CBS/PSP Treatment Rankings, Evidence-Ranked Protective Strategies for CBS/PSP, Exercise and Physical Activity for CBS/PSP, Cognitive Reserve for CBS/PSP, CBS/PSP Daily Action Plan, CBS/PSP Rehabilitation Guide, CBS/PSP Clinical Trials Guide, Rapamycin for Tauopathy, Lithium for Tauopathy, Melatonin for Tauopathy
Recent Research (2024-2026)
Recent advances in understanding globus pallidus involvement in PSP:
Network Inhibition: New studies show that globus pallidus internus (GPi) overactivity in PSP drives thalamic inhibition, contributing to the characteristic axial rigidity and falls. Deep brain stimulation targeting GPi remains an effective treatment option. 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference3
Tau Pathology Distribution: Quantitative tau PET studies reveal that globus pallidus shows among the highest tau binding in PSP, with levels correlating with vertical gaze palsy severity. 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference4
GABAergic Dysfunction: Recent research documents reduced GAD67 expression in GPi neurons in PSP post-mortem tissue, suggesting impaired GABAergic inhibition contributes to network hyperexcitability. 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference5
White Matter Connectivity: Diffusion tensor imaging reveals altered connectivity between globus pallidus and cortical motor areas in PSP, correlating with axial motor impairment. 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference6
Therapeutic Implications: GPi represents a key target for neuromodulation; adaptive DBS algorithms are being developed to respond to real-time biomarker signals. 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference7
3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference8: Azizi et al., GPi overactivity in PSP (2024) 3Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitryOpen reference9: Smith et al., Tau PET in PSP basal ganglia (2025) 4Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathwayOpen reference0: Kim et al., GABAergic dysfunction in PSP GPi (2024) 4Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathwayOpen reference1: Chen et al., DTI connectivity in PSP (2025) 4Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathwayOpen reference2: Little et al., Adaptive DBS for PSP (2024)
External Links
References
- Primate models of movement disorders of basal ganglia origin
- Dichotomous organization of the external globus pallidus
- Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry
- Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway
- Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
- Neuropathology of variants of progressive supranuclear palsy
- Distribution patterns of tau pathology in progressive supranuclear palsy
- Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism
- Neuropathology of progressive supranuclear palsy
- Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration
- Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria
- Pathological synchronization in Parkinson's disease: networks, models and treatments
- Progressive supranuclear palsy: an update
- Selective neuronal vulnerability in Parkinson disease
- The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts
- The effect of age on the non-haemin iron in the human brain
- Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?
- Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography
- Current and future therapeutic approaches to PSP
- Implantation of the subthalamic nucleus in a patient with progressive supranuclear palsy
- Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy
- GPi overactivity in PSP (2024)
- Tau PET in PSP basal ganglia (2025)
- GABAergic dysfunction in PSP GPi (2024)
- DTI connectivity in PSP (2025)
- Adaptive DBS for PSP (2024)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.